Up to 84% of adult asthma patients present with type 2 inflammation, which can be both local and systemic. DUPIXENT targets both IL-4 and IL-13 signaling, two of the key sources of type 2 inflammation in asthma. The mechanism of dupilumab action has not been definitively established.1-5,7,8
DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.1